Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NRX Pharmaceuticals, Inc.NRXP · Entity 6523 | Director · Chairman and Chief Scientist · 10% owner | April 09, 2025 | September 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NRX Pharmaceuticals, Inc.
Report date April 09, 2025 · Filed September 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2035-04-09 | Direct | 125,000 |
Reported balance
After 2025-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-09 · Grant · Acquired 125,000 · Balance 125,000 F1: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2025 Filed Sep 10, 2025 15:36 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001415889-25-024084 · form4-09102025_070903.xml · derivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chairman and Chief Scientist · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-04-09 F1 · price: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued Read SEC document |
| December 17, 2024 Filed Dec 18, 2024 08:27 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock | 40,000 | $1.17 | $46,800.00 |
DisclosureSEC source: 0001415889-24-029694 · form4-12182024_011233.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chairman and Chief Scientist · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,634 Read SEC document |
| August 23, 2023 Filed Aug 24, 2023 12:14 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock | 100,000 | $0.33 | $33,000.00 |
DisclosureSEC source: 0001104659-23-094815 · tm2324394-3_4seq1.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chief Scientist · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,332 Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 09:24 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock | 200,000 | $0.32 | $64,400.00 |
DisclosureSEC source: 0001104659-23-094406 · tm2324394-1_4seq1.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chief Scientist · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,332 Read SEC document |
| December 14, 2022 Filed Feb 14, 2023 17:14 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GiftCommon Stock, par value $0.001 per share | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002500 · form5-02142023_100203.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 14,468,329 F1 · kind: Donation of 300,000 shares from the Jonathan Javitt Living Trust to the Jonathan Javitt Donor Advised Fund. F2 · price: Charitable Transfer F3 · balance_after: Consists of (i) 12,599,997 shares of common stock held by the Jonathan Javitt Living Trust, (ii) 1,422,000 shares of common stock held by The Javitt 2012 Irrevocable Dynasty Trust, (iii) 146,332 shares of common stock held by Jonathan Javitt individually and (iv) 300,000 held by the Jonathan Javitt Donor Advised Fund. Jonathan Javitt is the trustee of the Jonathan Javitt Living Trust, the Grantor of The Javitt 2012 Irrevocable Dynasty Trust and the donor and primary advisor of the Jonathan Javitt Donor Advised Fund. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 16:33 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | SaleCommon Stock, par value $0.001 per share | 400,000 | $1.00 | $400,000.00 |
DisclosureSEC source: 0001415889-22-012324 · form4-12092022_091256.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 12,899,997 F1 · acquired: Private sale pursuant to an option granted by the Reporting Person in 2017 in support of a financing for NeuroRx, Inc. Purchaser has agreed to hold the shares for a period of one year. F2 · ownership.nature: Held by the Jonathan Javitt Living Trust. The Reporting Person is a trustee of the Trust. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 09:46 UTC Amendment | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock | 100,000 | $0.58 | $58,000.00 |
DisclosureSEC source: 0000921895-22-001874 · form4a13398002_06022022.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chief Scientist · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,332 Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 08:55 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock | 100,000 | $58.00 | $5,800,000.00 |
DisclosureSEC source: 0000921895-22-001872 · form413398002_06012022.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chief Scientist · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,332 Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:48 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantCommon Stock | 1,422,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-21-001945 · es210157190_4-javittj.xml · nonDerivative · entry 3 Javitt Jonathan C · CIK 0001303782 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,422,000 F1 · price: On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement). F2 · price: The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed May 24, 2021, the effective date of the Merger. F4 · ownership.nature: Held by The Javitt 2012 Irrevocable Dynasty Trust of which the Reporting Person is the Grantor. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:48 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantCommon Stock | 13,348,997 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-21-001945 · es210157190_4-javittj.xml · nonDerivative · entry 2 Javitt Jonathan C · CIK 0001303782 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 13,348,997 F1 · price: On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement). F2 · price: The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed May 24, 2021, the effective date of the Merger. F3 · ownership.nature: Held by the Jonathan Javitt Living Trust of which the Reporting Person is trustee. Read SEC document |
| May 24, 2021 Filed Jun 10, 2021 18:48 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | GrantCommon Stock | 46,332 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950142-21-001945 · es210157190_4-javittj.xml · nonDerivative · entry 1 Javitt Jonathan C · CIK 0001303782 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,332 F1 · price: On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement). F2 · price: The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed May 24, 2021, the effective date of the Merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.